Chinese hamster ovary (CHO) cell lines secreting a series of truncated forms of human immunodeficiency virus type I (HIV-1) IIIB (clone BHIO) gp120 were assembled. Using purified glycoproteins, we demonstrated the functional and structural integrity of these truncates by their reactivity with both sCD4 and anti-gp120 monoclonal antibodies (MAbs). Deletion of the V1, V2 and V3 regions had minimal effects on CD4 binding, but deletion of the NH 2 terminus affected the folding of the truncated molecule. Deletion of either V1/V2 or V1/V2/V3 regions led to enhanced recognition by some, but not all, HAlos mapping to the CD4 binding site. In contrast, deletion of the V1/V2 regions had no effect on the ability of V3-specific MAbs to bind to the truncate. These results support the use of truncated forms of gp120 as components of potential HIV vaccines.
Introduction
The primary interaction between the human immunodeficiency virus type I (HIV-1) envelope glycoprotein, gp120, and its cellular receptor CD4 represents an attractive target for antiviral drug design. Although details of the three-dimensional structure of the binding site on CD4 have been known for some time (Ryu et al., 1990; Wang et al., 1990) , complementary information on the site on gp120 has been slow to emerge. The complexity, flexibility and high level of glycosylation of the envelope protein have complicated structural studies and appear to have prevented its crystallization. Gp120 typically contains nine disulphide bonds and 24 N-linked glycosylation sites, resulting in approximately 50% of the observed molecular mass being carbohydrate. Comparisons of the sequences of envelope (Env) proteins from different HIV isolates have classified the gp120 molecule into five variable regions (V1 to VS) interleaved by five relatively conserved regions (C1 to C5) (Starcich et al., 1986; Modrow et al., 1987 ) (see Fig. 1 ).
Author for correspondence: R. L. Brady. One approach to elucidating the CD4 binding site on gp120 is to examine smaller, biologically active fragments that may be more amenable to structural analysis, as has been reported for the CD4 molecule (Ryu et al., 1990; Wang et al., 1990; Brady et al., 1993) . However, for gp120 no single domain responsible for receptor binding has been identified, and the site of CD4 interaction is believed to involve discontinuous residues in the polypeptide sequence (Olshevsky et a]., 1990) . Previous studies where truncated forms of gp 120rob from the HXB2 clone were expressed have identified regions of the gp120 linear sequence essential for maintenance of CD4 binding (Pollard et al., 1991 (Pollard et al., , 1992 Wyatt et al., 1993) . Although there is no clear domain structure, the V1, V2 and V3 regions, and parts of both termini, could be removed without disrupting CD4 binding. Most of these residues are unlikely to be directly involved in CD4 binding, but their presence may be required either to form supporting structures essential to maintain the conformation of the binding site or may be critical for the folding of the molecule into its active conformation. The observation that most of the conserved sequences are required to maintain functional folding is consistent with the concept that many of these regions may be buried in the native structure. This further suggests that removal of variable regions may lead to enhanced exposure of conserved gp120 regions, which may normally be exposed only by conformational changes accompanying the fusion process (Matthews et al., I994) . Thus, truncated forms of the gp120 molecule may be useful for vaccine development and may induce antibodies capable of recognizing epitopes conserved between divergent viral isolates (Pollard et al., 1992; Wyatt et al., 1993) .
In the present study, we describe the assembly of CHO cell lines secreting a series of deleted gp120 molecules from the BH10 clone of HIV-1IIIB. Because of the reported close relationship of CHO derived gp120 to viral gp120 (Moore ef al., 1990; Fenouillet et al., 1989) , mutant forms of gp120 were expressed in CHO L761 cells (Cockett et al., 1991) using the glutamine synthetase eukaryotic expression vector pEEl4 (Cockett et al., 1990; Bebbington et al., 1992; Kingston et al., 1992) . Using purified, soluble proteins we demonstrate the structural and functional integrity of the deleted proteins, measuring their reactivity both for soluble CD4 (sCD4) and for a panel of monoclonal antibodies (MAbs) specific for a range of epitopes within gp120. The results confirm that deletion of the V1, V2 and V3 regions has minimal effect on CD4 binding; however, deletion of the NH 2 terminus can affect the folding of the truncated molecule. Deletion of either V1/V2 or VI/V2/V3 regions leads to enhanced recognition by some, but not all, MAbs recognizing epitopes overlapping the CD4 binding site (CD4 bs). In contrast, deletion of the VI/V2 regions had no effect on the ability of MAbs specific for the V3 domain to bind. Our results confirm and extend earlier studies which employed truncates expressed either transiently in COS cells (Pollard et al., 1992) or in oligomeric forms on the surface of COS7 cells (Wyatt et al., 1993) . These results support the use of truncated forms of gpI20 as components of potential HIV vaccines.
Methods
• Construction of expression plasmids. Throughout this study, cDNA from the BH10 clone of the HIV LAI (IIIB) isolate was used. The sequence numbering of BH10 includes the signal peptide as described by Myers et al. (1988) with the expressed protein commencing at amino acid (aa) threonine-31 and ending at glutamic acid-510. To increase the Graphical representations of some of these data are given in Fig. 3 . Affinity constants as ratios with respect to gp120 are given in Fig. 4 Linsley et al. (1988) .
expression of secreted, heterologous proteins (Chapman eta] ., 1991) the signal peptide of BH10 was replaced by the signal sequence of the human tissue plasminogen activator (tpa) gene. A cassette containing the tpa leader sequence linked by a BglII restriction endonuclease (RE) site to gp120 aa 31-510 and flanked by 5'and 3' HindIII RE sites was ligated into the HindIII-digested eukaryotic expression vector pEEl4 to complete the pEE14/tpa/gp120 vector. For the generation of deleted forms, the gpI20 open reading frame (ORF) was removed by cleavage of the pEE14/tpa/gp120 vector with BglII and EcoRI to create the 'pEE14/tpa' vector and replaced by PCR-generated fragments containing BamHI and EcoRI RE sites at their 5' and 3' termini respectively. In those cases where two or more discontinuous fragments of gp120 were required, each fragment was cloned separately with suitable RE sites at the 5' and 3' termini into an intermediate plasmid vector (pAM1); the individual fragments were then digested and Iigated to generate the complete ORF, which was then transferred into 'pEE14/tpa'. For example, the gene for construct PR6 contained two fragments coding for aa 75-123 and 205-510. The first of two PCR-generated fragments, F1, aa 75-123, contained BamHI (5') and XbaI (3') while fragment F2, aa 205-510, contained XbaI (5') and EcoRI (3'). Two plasmids were created, pAM1/F1 and pAM1/F2, by cloning into the polylinker of pAMI. The BamHI/XbaI/F2 digested insert of pAM1/F2 was then ligated into BamHI/Xbal/F2 digested pAM1/F1 to create the PR60RF This was then subcloned into the BglII/EcoRI restricted pEE14/tpa/gp120 vector to create the PR6 construct. Details of all synthetic ORFs are shown in Fig. 1 .
• Expression of truncated gp120 mutants. All constructs were screened for their ability to express gp120 in transient expression assays prior to the establishment of stable cell lines. Stable ceil lines were established following transfection of CHO L76I cells with the appropriate expression plasmid as described in Bebbington et al. (1992) and Kingston et al. (1992) . Clones secreting high levels of gp120 were amplified by growth in increasing methionine sulphoximine (MSX) concentrations (up to 500 ,M) and the cell line producing the greatest concentration of soluble gp120 used for bulk production by growth for 3-4 days in cell factories (Nunc). The envelope glycoproteins were purified by affinity chromatography using D7324 polyclonal antiserum [raised against a synthetic peptide corresponding to the 15 COOH-terminal amino acids of gp120EmBIBH10 (Aalto BioReagents) coupled to Sepharose 4B (Pharmacia)]. Cell supernatants treated with protease inhibitors were passed over a column equilibrated with 20 mM-Tris pH 7'5--0'9% NaC1, washed with 20 mMTris--0'5 M-NaC1 and eluted with 2 M-MgC[= pH 6"0. Yields were typically 0"5-5'0 mg of gp120 mutant per litre of cell supematant. Samples were assessed by SDS-PAGE and immunoblots, using a polyclonal sera (ADP421) raised against CHO derived gp120¢mBlBH10.
• Binding assays. Three ELISA binding assays, based on procedures developed by Moore (1990) , were used employing D7324 as the capture assay antibody. Detection and quantification of gp120 and truncates were followed with either polyclonal rabbit antiserum raised against CHO expressed gp120 (ADP421) or with a pool of HIV-positive human sera and detection with a suitable anti-species IgG conjugated to horseradish peroxidase (HRP) (SeraLabs) and TMB (Murex). sCD4 binding was determined indirectly using the anti-CD4 MAb ADP359 and anti-mouse IgG-HRP. The ability of all the gpI20 specific MAbs to bind to the gpI20 proteins was determined by using an appropriate antispecies IgG-HRP (SeraLabs). Further details of the MAbs used are given in Table 1 . The amount of truncated gp120 (> 1 p,g/ml) used in all assays was sufficient to fully saturate the D7324 binding sites and all of the truncates were found to bind to D7324 with very similar affinities to full-length gpI20.
Human sera were collected from I0 healthy CDC stage II and Ill seropositive males attending a sexually transmitted disease clinic as part of a longitudinal study of the natural history of infection (Came et al., 1987) . These individuals had not received anti-retroviral therapy at the time of sampling.
Results

Production of gp120 constructs and CD4 binding
The expressed products can be grouped into three classes: (a) continuous segments of the gpI20 polypeptide chain (PRI-5), (b) loop deletions starting at aa 93 (PR8, 9) and (c) loop deletions similar to those in (b) but with an extended NH~-tenninus beginning at position 75 (PR6, 12) (Fig. 1) . Additionally, full-length gp120 was expressed in the same system for use as a control. In each case, expression of the gene product was detected by ELISA and immunoblot assays in supernatant from transient cell cultures prior to establishment of stable cell lines. Cell lines secreting truncates PR6, 8, 9 and 12 were amplified with MSX and produced soluble protein in the range 0"5-5 mg/litre. These products were readily purified by the immunoaffinity method described. Analysis of truncates by SDS--PAGE and Western blotting showed that the purified proteins migrated as a single species, with the exception of gpI20 which showed the characteristic cleavage (< 20%) in the V3 loop giving rise to two fragments of 50 kDa and
0.001 0.01 0.1 1 10 100 sCD4 (p,g/ml) Fig. 2 . Affinity of sCD4 for gp120, PR6, PRS, PR9 and PR12. Increasing concentrations of sCD4 were allowed to react with saturating concentrations of gp120, PR6 or PR12 captured by Aalto D7324. Bound sCD4 was detected with anti-CD4 lAb ADP359. 70 kDa (data not shown) . In all cases, the observed molecular masses of the products were consistent with their predicted values. Attempts to obtain crystals of PR6 and PR12 for structural analysis have to date been unsuccessful. All of the soluble proteins were tested for their ability to bind sCD4. GpI20, PR6 and PR12 were found to bind sCD4 at concentrations of 0"03, 0"07 and 0"19 gg/ml, respectively, resulting in half maximal binding (Fig. 2) . In contrast, all of the remaining proteins, including PR8 and 9, failed to bind sCD4 (data not shown).
Monoclonal antibody binding studies
Proteins PR1, 8 and 9 bound MAb 38.1a, recognizing a linear epitope within C4, but failed to bind any of the conformation-dependant MAbs suggesting that deletion of the NH2-termina] amino acids 75-92 results in a series of incorrectly folded proteins. These data explain the inability of these proteins to bind sCD4. However, both PR6 and PR12, with less deleted NH 2 termini, were capable of binding MAbs specific for epitopes overlapping the CD4 bs, V3 and C4 regions ( Table 1) . Deletion of the V1, V2 region did not affect the ability of V3 MAbs to recognize PR6. MAb 38.1a had 10--20 fold increased binding to both the PR6 and PR12 proteins. In contrast, MAb 13H8 mapping to an adjacent epitope in the C4 region showed only a 3-4"5 fold increase in its recognition of PR6 and PR12, respectively. Only MAbs 10/46c and 39.3b, within the group of MAbs recognizing epitopes overlapping CD4 bs, demonstrated significant increase in their recognition of PR6 and PR12 (Table 1, Figs 3  and 4 ). Furthermore, we tested the ability of a panel of human sera from HIV-infected individuals to react with recombinant gp 120 or PR12 (Table 2 ). There was no significant reduction in the affinities of the sera for the deleted PR12 protein, suggesting that the majority of serum antibodies capable of binding BH10 gp120 are specific for conserved epitopes.
Discussion
We find that deletion of the V1, V2 and V3 regions from gp120 results in proteins capable of binding CD4 with an affinity comparable to that of the full-length protein. This is in agreement with earlier reports where truncated gp120 proteins were shown to bind to CD4 in non-quantitative radioimmunoprecipitation assays (Pollard et al., 1992; Wyatt ct al., 1993) . Pollard et al. (1992) reported on the ability of a panel of gp1201iiB (HXB2 clone) deletion mutants to bind sCD4, suggesting a minimal length binding construct (ENV59) comprising residues 93-117, 207-298 and 329-491, i.e. with V1, V2, V3, the COOH terminus and part of C1 deleted. CD4 binding was measured by co-precipitation with CD4 after metabolic labelling of gp120. In the present study, deletions of equivalent sites within the BH10 clone were constructed (PR8 residues 93-123, 205-299, 329-510) although an intact COOH terminus was retained to enable immunoaffinity purification. Both PR8 and PR9 (AV3) failed to bind any conformation dependent MAbs suggesting that their failure to bind sCD4 was attributable to incorrect folding. This discrepancy may be clone-related, there being six amino acid changes between HXB2 and BH10 within these parts of the sequence (N94D, A276V, Q291T, K404E, E430K, P471L). However, deletion mutants described by Moore et al. (1994) comprised sequences from both the HXB2 and BH10 clones and showed no sensitivity to this combination of different sequences, suggesting tolerance in the protein fold for these small sequence variations. Alternatively, the inconsistency may arise from either the different COOH termini of the proteins or from the use of different expression systems. However, it is clear that further extension of the NH 2 terminus to residue 74 (construct PR12) restored correct folding and CD4 binding. This pattern was also observed in constructs where the V3 region was retained, such that PR6 (starting at aa 75) bound CD4 whereas PR9 (starting at aa 93) failed to bind CD4. Earlier studies (Pollard et al., 1991 (Pollard et al., , 1992 Dowbenko et al., 1988; Syu et al., 1990 ) also exemplify the sensitivity of CD4 binding to alterations in the NH~-terminal region of gp120. One interpretation is that the terminal region forms a discrete domain which can be deleted in its entirety (ENV59) whereas deletion of part of this domain leaving a partial fragment may lead to misfolding.
The CD4 binding constants calculated for mutants PR6 and PRI2 and the wild-type gp120 are similar to those obtained previously for recombinant gpI20 (Moore, 1990 ) and multimeric gpi20 expressed on the surface of H9 CD4 + cells . This is consistent with a folded structure of this region closely akin to wild-type gp120. PR12 binds CD4 with lower affinity than wild-type gp120, suggesting that the V3 region may be acting to stabilize complex formation by holding gp120 in a more rigid conformation. However, the high affinity of these truncated forms for CD4 indicates co-crystallization of the receptor complex, and further complexes with MAbs may be feasible. M A b binding studies can be used to interpret a wide variety of functional parameters. In particular, MAbs known to map to conformational-dependent epitopes, such as some of those to the CD4 binding site, provide good evidence for correct folding. As preparations of recombinant gp120 are frequently heterogeneous and may contain populations of fully, partially and non-denatured molecules, we have taken care to compare proteins prepared within the same expression system and purified under identical conditions. In the present study, both PR6 and PRI2 show significant increases in their binding to MAbs mapping to epitopes overlapping the CD4 bs (39.3b, 10/46c and 38.ia). This enhancement is likely to result from removal of the V1/V2 region, being evidenced in both PR6 and PR12 and is consistent with a requirement for conformational change in gp120 accompanying CD4 binding. This may be a response to partial occlusion of the CD4 binding iiiiiiiiiii i !iiiiii i iiiiiiiiiiiiiiiiiiiiiiiii site by the V1/V2 region or reflect increased molecular flexibility resulting from removal of this region. It is of interest to note that both 39.3b and 10/46c were raised in rats immunized with rgpI20, whereas MAbs 428, 588 and 599 were obtained from HIV-1 infected individuals. This suggests that the latter group of MAbs recognizes epitope(s) more readily accessible on the native molecule, whereas MAbs raised to a recombinant antigen in the presence of Freund's adjuvant demonstrate enhanced binding to the deleted nonnative forms of gp120. We have previously reported that these human MAbs can partially compete with 39.3b for gp120 binding (McKeating et al., 1993) which is consistent with the conclusion that these rat and human MAbs recognize crossreactive but distinct epitopes (McKeating et al., 1992 a) . Similarly, Wyatt et al. (1993) reported that a V1/V2/V3 envelope deletion mutant of HXB2, expressed at the cell surface, bound CD4 bs MAbs with up to 50-fold higher affinity than full-length protein. Hence, the variable loops mask some discontinuous conserved epitopes in both oligomeric and monomeric gp120.
It is well established that HIV-infected individuals make a dominant immune response to the V2 and V3 loops. As the V2/V3 sequence of IIIB is not representative of sequences found in vivo in the infected population, then such antibodies in human sera will not be able to bind to the V2/V3 epitopes present on IIIB. This may explain the human serum results with full-length gp120 and PR12, showing that the sera recognize both equivalently (Table 2) . However, a vaccine that could elicit type-specific responses to such variable regions is not desirable; hence deletion of such variable loops may result in an immunogen which is capable of inducing an antibody response to the conserved regions. Given this premise, a IIIBloop deleted protein exposes the same conserved regions as are present in other strains of gp120 and is thus a reasonable starting point for such studies. A manuscript in preparation describes the immunogenicity of PR12 and its ability to induce a broad, cross-clade neutralizing response.
Detailed knowledge of gp120 structure is vital for both rational design of drugs and development of HIV vaccines incorporating all or part of the envelope glycoprotein. Important structural information has been derived from the elucidation of the disulphide bonding pattern and N-linked glycosylation distribution (Leonard et al., 1990) and the definition of variable and conserved gpI20 domains (Modrow et al., 1987; Starcich et al., 1986) . In addition, antigenic characterization of mutant envelope proteins has helped to elucidate inter-domain relationships (Kowalski et al., 1987; Thali et al., 1991a Thali et al., , b, 1992 Thali et al., , 1993 Wyatt et al., 1993 ; Moore et al., , 1994 . The cloning, purification and characterization of the gp120 truncates described in this study provides a further tool for investigating the structure and function of gpI20.
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